Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety profile of the proton-pump inhibitors
Autore:
Reilly, JP;
Indirizzi:
Dept Vet Affairs Med Ctr, New York, NY 10010 USA Dept Vet Affairs Med CtrNew York NY USA 10010 tr, New York, NY 10010 USA Arnold & Marie Schwartz Coll Pharm, Brooklyn, NY USA Arnold & Marie Schwartz Coll Pharm Brooklyn NY USA arm, Brooklyn, NY USA Long Isl Univ, Brooklyn, NY USA Long Isl Univ Brooklyn NY USALong Isl Univ, Brooklyn, NY USA
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
, volume: 56, anno: 1999, supplemento:, 4
pagine: S11 - S17
SICI:
1079-2082(199912)56:<S11:SPOTPI>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
HELICOBACTER-PYLORI INFECTION; MULTIPLE-DOSE OMEPRAZOLE; ACID-RELATED DISORDERS; REFLUX ESOPHAGITIS; DRUG-INTERACTIONS; THERAPEUTIC USE; GASTRIC-JUICE; LANSOPRAZOLE; PHARMACOKINETICS; PANTOPRAZOLE;
Keywords:
dosage schedules; drug interactions; gastrointestinal drugs; toxicity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
56
Recensione:
Indirizzi per estratti:
Indirizzo: Reilly, JP Dept Vet Affairs Med Ctr, 423 East 23rd St, New York, NY 10010 USA Dept Vet Affairs Med Ctr 423 East 23rd St New York NY USA 10010
Citazione:
J.P. Reilly, "Safety profile of the proton-pump inhibitors", AM J HEAL S, 56, 1999, pp. S11-S17

Abstract

The adverse effect profile of proton-pump inhibitors is presented. The proton-pump inhibitors are a well-tolerated class of drugs. The most common adverse events of headache, diarrhea, and nausea have been reported in fewer than 5% of patients treated with lansoprazole or omeprazole. The frequency of these adverse events with the two proton-pump inhibitors is comparable to that of placebo and histamine H-2-receptor antagonists. Few clinically important interactions have been observed between proton-pump inhibitors and other drugs metabolized by the cytochrome P-450 system. The interaction potential should be considered when drugs with a narrow therapeutic window, such as phenytoin, warfarin, and theophylline, are used con comitantly with proton-pump inhibitors. Theoretical concerns about the consequences of chronic administration of proton-pump inhibitors, such as the impact of sustained hypergastrinemia on gastric morphology and the development of atrophic gastritis, have been dismissed. While increased gastrin levels are observed among patients taking proton-pump inhibitors, for the majority they remain within the normal range. After long-term use of the drugs, patients do not appear to be at increased risk of atrophic gastritis or gastric cancer. Helicobacter pylori infection, rather than acid suppression, may be themore important factor for the development of atrophic gastritis. Bacterialovergrowth and altered nutrient absorption resulting from sustained hypochlorhydria induced by chronic administration of proton-pump inhibitors have not been realized as clinical concerns. Not only are proton-pump inhibitors well tolerated during short-term administration, but there also do not appear to be clinically important adverse sequelae associated with their long-term use.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 03:05:13